Kliiniset tutkimukset Nct sivu
Clinical Trial Results:
Phase 3, Multi-center, double-blind, randomized, parallel group study of the efficacy, safety, and tolerability of fixed combination torcetrapib (CP-529,414)/Atorvastatin administered orally, once daily (QD) for six months, compared with maximally tolerated Atorvastatin therapy alone, in subjects with heterozygous familial hypercholesterolemia.
| Summary | |
EudraCT number | 2004-004269-14 |
Trial protocol | SE DK IS |
Global completion date | 03 Mar 2006 |
| Paediatric regulatory details | |
Is the trial part of an agreed EMA paediatric investigation plan? | No |
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | No |
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | No |
| Results information | |
Results version number | v1(current) |
This version publication date | 24 Aug 2016 |
First version publication date | 24 Aug 2016 |
Other versions | |
Summary report(s) | A5091026_Public Disclosure Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03 for further information.